News

FDA to remove Black Box warning from hormone replacement therapy, marking major shift in menopause care

The FDA has removed a long-standing black box warning from menopause hormone therapies. This decision reverses decades of caution stemming from earlier research. Health officials now state that past concerns about breast cancer, dementia, and cardiovascular issues were overstated. This move restores treatment options for millions of women experiencing menopause symptoms.